Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative sensitivity of automated (Abbott M2000) and manual plasma HIV-1 RNA PCR assays for the detection of persistent viremia after long-term antiretroviral therapy.
Tosiano MA, Mar H, Hoeth D, Eron JJ, Gandhi RT, McMahon DK, Bosch RJ, Mellors JW, Cyktor JC; A5321 Team. Tosiano MA, et al. Among authors: gandhi rt. J Virus Erad. 2022 Nov 29;8(4):100095. doi: 10.1016/j.jve.2022.100095. eCollection 2022 Dec. J Virus Erad. 2022. PMID: 36479541 Free PMC article.
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.
Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, Lehmann C, Springer SA, Sax PE, Thompson MA, Benson CA, Buchbinder SP, Del Rio C, Eron JJ Jr, Günthard HF, Molina JM, Jacobsen DM, Saag MS. Gandhi RT, et al. JAMA. 2023 Jan 3;329(1):63-84. doi: 10.1001/jama.2022.22246. JAMA. 2023. PMID: 36454551
Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy.
Lian X, Seiger KW, Parsons EM, Gao C, Sun W, Gladkov GT, Roseto IC, Einkauf KB, Osborn MR, Chevalier JM, Jiang C, Blackmer J, Carrington M, Rosenberg ES, Lederman MM, McMahon DK, Bosch RJ, Jacobson JM, Gandhi RT, Peluso MJ, Chun TW, Deeks SG, Yu XG, Lichterfeld M. Lian X, et al. Among authors: gandhi rt. Cell Host Microbe. 2023 Jan 11;31(1):83-96.e5. doi: 10.1016/j.chom.2022.12.002. Epub 2023 Jan 2. Cell Host Microbe. 2023. PMID: 36596305 Free PMC article.
HIV post-treatment controllers have distinct immunological and virological features.
Etemad B, Sun X, Li Y, Melberg M, Moisi D, Gottlieb R, Ahmed H, Aga E, Bosch RJ, Acosta EP, Yuki Y, Martin MP, Carrington M, Gandhi RT, Jacobson JM, Volberding P, Connick E, Mitsuyasu R, Frank I, Saag M, Eron JJ, Skiest D, Margolis DM, Havlir D, Schooley RT, Lederman MM, Yu XG, Li JZ. Etemad B, et al. Among authors: gandhi rt. Proc Natl Acad Sci U S A. 2023 Mar 14;120(11):e2218960120. doi: 10.1073/pnas.2218960120. Epub 2023 Mar 6. Proc Natl Acad Sci U S A. 2023. PMID: 36877848 Free PMC article.
The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells.
Copertino DC Jr, Holmberg CS, Weiler J, Ward AR, Howard JN, Levinger C, Pang AP, Corley MJ, Dündar F, Zumbo P, Betel D, Gandhi RT, McMahon DK, Bosch RJ, Linden N, Macatangay BJ, Cyktor JC, Eron JJ, Mellors JW, Kovacs C, Benko E, Bosque A, Jones RB; AIDS Clinical Trials Group (ACTG) A5321 Team. Copertino DC Jr, et al. Among authors: gandhi rt. JCI Insight. 2023 Sep 22;8(18):e169028. doi: 10.1172/jci.insight.169028. JCI Insight. 2023. PMID: 37581929 Free PMC article.
Predictors of HIV rebound differ by timing of antiretroviral therapy initiation.
Li JZ, Melberg M, Kittilson A, Abdel-Mohsen M, Li Y, Aga E, Bosch RJ, Wonderlich ER, Kinslow J, Giron LB, Di Germanio C, Pilkinton M, MacLaren L, Keefer M, Fox L, Barr L, Acosta E, Ananworanich J, Coombs R, Mellors J, Deeks S, Gandhi RT, Busch M, Landay A, Macatangay B, Smith DM; AIDS Clinical Trials Group A5345 Study Team. Li JZ, et al. Among authors: gandhi rt. JCI Insight. 2024 Feb 8;9(3):e173864. doi: 10.1172/jci.insight.173864. JCI Insight. 2024. PMID: 38329130 Free PMC article.
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial.
Evering TH, Moser C, Jilg N, Ritz J, Wohl DA, Li JZ, Margolis D, Javan AC, Eron JJ, Currier JS, Daar ES, Smith DM, Hughes MD, Chew KW; ACTIV-2/A5401 Study Team. Evering TH, et al. EClinicalMedicine. 2024 Aug 16;75:102787. doi: 10.1016/j.eclinm.2024.102787. eCollection 2024 Sep. EClinicalMedicine. 2024. PMID: 39252866 Free PMC article.
The severity of COVID-19 across the spectrum of HIV.
Miller KW, Gandhi RT. Miller KW, et al. Among authors: gandhi rt. Curr Opin HIV AIDS. 2023 May 1;18(3):119-125. doi: 10.1097/COH.0000000000000791. Epub 2023 Mar 17. Curr Opin HIV AIDS. 2023. PMID: 37144613 Free PMC article. Review.
242 results